During the past decade, CAPRISA eThekwini CRS conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 7 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 5 clinical trials were completed. i.e. 62.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CAPRISA eThekwini CRS" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 4 trials, followed by "HIV Vaccine Trials Network" with 3 trials sponsored, "AIDS Clinical Trials Group" with 2 trials sponsored, "COVID-19 Prevention Network" with 2 trials sponsored and "Centre for the AIDS Programme of Research in South Africa" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CAPRISA eThekwini CRS" #1 collaborator was "National Institute of Allergy and Infectious Diseases (NIAID)" with 10 trials as a collaborator, "HIV Prevention Trials Network" with 2 trials as a collaborator, "AIDS Clinical Trials Group" with 1 trials as a collaborator, "Bill and Melinda Gates Foundation" with 1 trials as a collaborator and "Centre for the AIDS Programme of Research in South Africa" with 1 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "CAPRISA eThekwini CRS" are "HIV Infections" (5 trials), "COVID-19" (3 trials), "HIV Infection" (3 trials), "SARS-CoV-2" (2 trials) and "Tuberculosis" (2 trials). Many other conditions were trialed in "CAPRISA eThekwini CRS" in a lesser frequency.

Most popular intervention types in "CAPRISA eThekwini CRS" are "Biological" (7 trials), "Other" (6 trials), "Drug" (3 trials), "Diagnostic Test" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Sample collection" (2 trials), "ALVAC-HIV" (1 trials), "ALVAC-HIV (vCP2438) Placebo" (1 trials) and "Ad26.COV2.S" (1 trials). Other intervention names were less common.

The vast majority of trials in "CAPRISA eThekwini CRS" are 13 trials for "All" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "CAPRISA eThekwini CRS". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in CAPRISA eThekwini CRS, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CAPRISA eThekwini CRS, 3 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".